Clinical trial
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients…
NCT00475956 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00475956 |
|---|---|
| Title | Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours |
| Official title | Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients With Advanced Solid Tumours |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | AZD2171, AZD0530 |
| Enrollment | 40 |
| Start date | May 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | May 21, 2007 |
| Last update posted | Apr 15, 2010 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: